ClinicalTrials.gg
Active, not recruitingNCT04841811APPROACHUpdated May 22, 2026

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

A Phase 3 interventional study of Almonertinib in Lung Cancer, sponsored by Guangdong Association of Clinical Trials. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Guangdong Association of Clinical Trials · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing aumolertinib in Lung Neoplasms — 3 open to participants now, 5 under way, 2 of them phase 3. aumolertinib · Lung Neoplasms.

Planned enrollment
Largest of 10
192 · median 40
Started
2022
with 3 others
Phase 3
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
1 of 10
Guangdong Association of Clinical Trials

Among the 10 studies testing aumolertinib in Lung Neoplasms, this one has the largest planned enrollment, is one of 4 that started in 2022, is the only one in phase 3, and was the 4th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 10 studies testing aumolertinib in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing aumolertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell lung cancer, and to evaluate the effectiveness and safety of dynamic MRD guided maintenance therapy with almonertinib after induction therapy with almonertinib and local therapy (radical surgery or radiotherapy) evaluated by MDT diagnostic model. The study includes a screening period (not more than 28 days after the subject with signed informed consent before first medication), treatment period (including induction therapy with almonertinib\ radical therapy under MDT model\ consolidation therapy with almonertinib) and follow-up period.

Read the detailed description

This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell lung cancer, and to evaluate the effectiveness and safety of dynamic MRD guided maintenance therapy with almonertinib after induction therapy with almonertinib and local therapy (radical surgery or radiotherapy) evaluated by MDT diagnostic model. The study includes a screening period (not more than 28 days after the subject with signed informed consent before first medication), treatment period (including induction therapy with almonertinib\ radical therapy under MDT model\ consolidation therapy with almonertinib) and follow-up period.

Eligible subjects receive 110 mg of almonertinib once a day for 8 consecutive weeks of induction therapy; local treatment (surgical or radical radiotherapy) is selected after MDT assessment. Subjects will be randomly assigned to groups A and B. Stratification factors included EGFR 19deletion or EGFR 21L858R mutation; shedding or non-shedding ctDNA at baseline; radical surgery or radiotherapy under MDT model.

Subjects in group A will receive 110 mg of almonertinib once a day for 2 years. Imaging evaluation is conducted every 12 weeks. Subjects in group B will receive almonertinib guided by dynamic MRD monitoring. When ctDNA was positive (MRD+), subjects will receive 110 mg of almonertinib once a day for 12 weeks; when ctDNA was negative (MRD-), subjects will stop almonertinib and be observed for 12 weeks. This model will continue until disease recurrence or metastasis.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • unresectable stageIII NSCLC
  • EGFR mutation
  • MDT
  • ctDNA MRD
  • adaptive deescalation treatment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be included in this study:

  1. Over 18 years old (including 18 years old) and under 70 years old (including 70 years old).
  2. The (ECOG) physical status score is 0 or 1, and there is no deterioration within 2 weeks before the study drug treatment, and the expected survival period is not less than 12 weeks.
  3. Stage III non-squamous cell non-small cell lung cancer confirmed by histopathology or cytology and determined by the investigator to be unresectable (International Association for the Study of Lung Cancer Eighth Edition Lung Cancer Staging).
  4. Tumor tissue samples or blood samples, pleural effusions, ascites effusions, and pericardial effusions are confirmed to be EGFR sensitive mutations (ie, exon 19 deletion or L858R, alone or coexisting, Or with other EGFR mutations, but patients with EGFR20 exon insertion mutations cannot be included in the group) by laboratory tests approved by the investigator.
  5. According to the RECIST1.1 standard, the subject must have at least one imaging . The baseline tumor imaging evaluation was performed within 28 days before the first medication.
  6. Women of childbearing age should take appropriate measures from screening to 3 months after stopping the study treatment and should not breastfeed. Before starting the administration, the pregnancy test is negative, or meeting one of the following criteria proves that there is no risk of pregnancy:

    1. is defined as age greater than 50 years,and amenorrhea for at least 12 months after stopping all exogenous hormone replacement therapy.
    2. For women younger than 50 years old, if the amenorrhea is 12 months or more after stopping all exogenous hormone treatments, and the luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels are within the laboratory postmenopausal reference value range, also It can be considered postmenopausal.
    3. Have received irreversible sterilization, including hysterectomy, bilateral ovariectomy or bilateral fallopian tube resection, except for bilateral fallopian tube ligation.
  7. Male subjects should use barrier contraception (ie, condoms) from screening to 3 months after the study treatment is stopped.
  8. The subjects themselves participated voluntarily and signed a written form.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria cannot be included in this study:

  1. Have received any of the following treatments:

    1. Have received lung surgery in the past;
    2. Have used any EGFR tyrosine kinase inhibitor in the past;
    3. Previously received any systemic chemotherapy or immunotherapy for lung cancer;
    4. Receive any lung cancer radiotherapy in the past;
  2. The patient has undergone open surgery on other parts except the lungs within 14 days before using the study drug for ≤14 days.
  3. In addition to NSCLC, another malignant disease has been diagnosed in the past 5 years (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, and cervical carcinoma in situ).
  4. Have used proprietary Chinese medicines with anti-tumor effects in the past. Those who have used proprietary Chinese medicines with anti-tumor effects but have been used for no more than 7 days and have been stopped for 2 weeks or more before the drug treatment in this study can be included in the group.
  5. There are serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney disease, (LVEF) \< 50%, uncontrolled hypertension [that is, it is still greater than or equal to level 3 hypertension after drug treatment]); suffering from swallowing dysfunction, active gastrointestinal disease, or other significant effects on the absorption of oral drugs, Disorders of distribution, metabolism, and excretion. Those who have had most gastrectomy operations in the past.
  6. Fever and body temperature above 38℃ in the past week, or active infection with clinical significance. Active tuberculosis. Active fungal, bacterial and/or viral infections requiring systemic treatment.
  7. Those who have active bleeding, new thrombotic diseases, are taking anticoagulant drugs, or have bleeding tendency;
  8. The resting has major abnormalities in rhythm, conduction, or morphology, such as complete left bundle branch block, heart block above Ⅱ degree, clinically significant ventricular arrhythmia or atrial fibrillation, Unstable angina pectoris, congestive heart failure, chronic heart failure grade ≥ 2 by the (NYHA).
  9. Myocardial infarction, coronary artery/peripheral artery bypass or cerebrovascular accident occurred within 3 months.
  10. The (QTc) of 12-lead ECG is ≥450 ms for males and ≥470 ms for females.
  11. There are risk factors that lead to prolonged QT interval or risk factors that increase arrhythmia, such as heart failure, ≥CTCAE (version 4.03) 2nd degree hypokalemia (2nd degree hypokalemia is defined as: serum potassium \<the lower limit of the normal value is 3.0mmol/L, and there are symptoms and needs treatment), congenital long QT syndrome, family history of long QT syndrome.
  12. Any drug known to prolong the QT interval is being used within 2 weeks before the first dose.
  13. Insufficient bone marrow reserve or organ function, reaching any of the following laboratory limits (no corrective treatment within 1 week before laboratory examination of blood):

    1. \<1.5×109 / L;
    2. count \<90×109 / L;
    3. \<90 g/L (\<9 g/dL);
    4. > 3 times the (ULN);
    5. Aspartate aminotransferase>3×ULN
    6. Total > 1.5×ULN;
    7. Creatinine> 1.5×ULN or rate \<45 mL/min (calculated by Cockcroft-Gault formula);
    8. Serum albumin (ALB) \<28 g/L;
  14. Female subjects who are pregnant, lactating, or planning to become pregnant during the study period.
  15. A history of interstitial lung disease, a history of drug-induced interstitial lung disease, a history of interstitial pneumonia requiring therapy, or any evidence of clinically active interstitial lung disease.
  16. Have a history of to any active or inactive ingredients of Almonertinib, or to drugs with similar chemical structure to Almonertinib or in the same category as Almonertinib.
  17. Any serious or uncontrolled eye disease (especially severe dry eye syndrome, dry keratoconjunctivitis, severe exposure keratitis or other diseases that may increase epithelial damage), according to the doctor's judgment, it may increase the safety risk of the subject; or patients with eye abnormalities who require surgery or are expected to require surgical treatment during the study period.
  18. Use/consumption of drugs or foods that are known to have potent inhibitory effects within 2 weeks, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefa Oxazolone, nelfinavir, ritonavir, saquinavir, telithromycin, aceto-eandomycin, voriconazole, and grapefruit or grapefruit juice.
  19. Use drugs known to have potent CYP3A4 inducing effects within 2 weeks, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin and Hypericum perforatum.
  20. Use drugs that are CYP3A4 substrates (with a narrow therapeutic index) within 2 weeks, including but not limited to dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine.
  21. Have used strong P-gp inhibitors (including but not limited to verapamil, cyclosporin A, dexverapamil) within 2 weeks.
  22. Subjects judged by the investigator who may not be in compliance with the research procedures and requirements, such as subjects who have a clear history of neurological or mental disorders (including epilepsy or dementia), currently suffering from mental disorders, etc. .
  23. The investigator judges that there are any subjects that endanger the safety of the subject or interfere with the evaluation of the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (estimated)

Study arms

  • Active comparator
    Group A (almonertinib continuous treatment)

    Subjects will be randomly assigned to groups A and B after radical therapy (surgery or radiothrapy) and will receive 110 mg of almonertinib once a day for 2 years or until disease recurrence or metastasis.

    Drug: Almonertinib

  • Experimental
    Group B (ctDNA monitoring guided the almonertinib treatment)

    Subjects will be randomly assigned to group B after radical therapy (surgery or radiothrapy) and will receive almonertinib guided by ctDNA dynamic monitoring (every 3 months test ctDNA once, if it is positive, continue to receive almonertinib 110 mg once a day, if it is negative, stop almonertinib until ctDNA turns positive and receive almonertinib treatment again).

    Drug: Almonertinib

Interventions

  • DrugAumolertinibStudies of AumolertinibAumolertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy

    Also known as: ctDNA dynamic monitoring guided the Almonertinib treatment

06

What researchers measure

Primary outcomes

  1. Assess the anti-tumor activity by IRC: ORR

    The objective response rate (ORR) was assessed by IRC for all eligible subjects after 8 weeks of Almonertinib induction therapy. Until the disease progresses or in the absence of disease progression, the last evaluable data will be recorded in the ORR assessment. However, any CR or PR that occurs after the termination of the study treatment and receiving further anti-tumor therapy will not be included in the ORR calculation.

    Time frame: 8 weeks

  2. Assess the anti-tumor activity by IRC: Event free survival (EFS) rate

    The 18 months event-free survival period is defined as the time from random to the occurrence of any of the following events within 18 months, whichever occurs first: Tumor progression assessed by IRC according to RECIST 1.1; Tumor recurrence confirmed by IRC, including local recurrence or distant metastasis; Death caused by any cause.

    Time frame: 18 months

Secondary outcomes

  1. Assess the anti-tumor activity by investigators: ORR

    The objective response rate (ORR) was assessed by investigators for all eligible subjects after 8 weeks of Almonertinib induction therapy. Until the disease progresses or in the absence of disease progression, the last evaluable data will be recorded in the ORR assessment. However, any CR or PR that occurs after the termination of the study treatment and receiving further anti-tumor therapy will not be included in the ORR calculation.

    Time frame: 8 weeks

  2. Assess the anti-tumor activity by investigators: Event free survival (EFS)

    The 18 months event-free survival period is defined as the time from random to the occurrence of any of the following events within 18 months, whichever occurs first: Tumor progression assessed by investigators according to RECIST 1.1; Tumor recurrence confirmed by investigators, including local recurrence or distant metastasis; Death caused by any cause.

    Time frame: 18 months

  3. Event free survival (EFS)

    The event-free survival period is defined as the time from random to the occurrence of any of the following events, whichever occurs first: Tumor progression assessed by IRC according to RECIST 1.1; Tumor recurrence confirmed by IRC, including local recurrence or distant metastasis; Death caused by any cause.

    Time frame: 2 years

  4. Overall survival (OS)

    Overall survival is defined as the time between the date of first administration and the date of death of the subject for any reason.Subjects not dead at the time of the statistical analysis will be truncated at the time when the subject was last known to be alive.

    Time frame: more than 2 years

  5. Major pathological response (MPR)

    The major pathological response rate is defined as the incidence of tumor regression induced by neoadjuvant therapy with pathological residual tumor ≤10% (only applicable to subjects who have received surgical treatment).

    Time frame: 8 weeks

  6. Assess the safety of Almonertinib

    To evaluate number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 2 years

  7. Quality of life(QOL) assessed by EORTC QLQ-C30

    Quality of Life assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30(EORTC QLQ-C30)

    Time frame: 2 years

07

Study locations

1 site
  • Guangdong Lung cancer institute
    Guangzhou, Guangdong 510080, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 65 non-industry phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 99. This study's planned 54 months is below that.

Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2021
First posted
Apr 12, 2021
StartActual
Jun 20, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04841811
Lead sponsor
Guangdong Association of Clinical Trials
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Jun 20, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Q. Zhou
principal investigator · Guangdong Provincial People's Hospital
Y. Pan
principal investigator · Guangdong Provincial People's Hospital
X-N. Yang
principal investigator · Guangdong Provincial People's Hospital
A-W. Liu
principal investigator · Second Affiliated Hospital of Nanchang University
W-N. Feng
principal investigator · First People's Hospital of Foshan
L-H. Sun
principal investigator · The First Affiliated Hospital of Nanchang University
T-M. Zhang
principal investigator · Beijing Chest Hospital, Capital Medical University
X-R. Dong
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
M-F. Zhao
principal investigator · First Hospital of China Medical University
H. Zhang
principal investigator · The Affiliated Hospital of Xuzhou Medical University
Y. Fan
principal investigator · Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute)
Y. Yang
principal investigator · The Third People's Hospital of Chengdu
P-L. Wang
principal investigator · Zhejiang University
Q-W. Meng
principal investigator · The Affiliated Cancer Hospital of Harbin Medical University,
R-R. Zhou
principal investigator · The Xiangya Hospital of Central South University
Y-S. Shu
principal investigator · Northern Jiangsu People's Hospital
B-H. Wang
principal investigator · Northern Jiangsu People's Hospital
H-P. Xu
principal investigator · Fujian Cancer Hospital
J. Li
principal investigator · Sichuan Cancer Hospital and Research Institute
H. Luo
principal investigator · Cancer Hospital of Jiangxi Province
Q. Bu
principal investigator · First Affiliated Hospital of Guangxi Medical University
H-J. Wang
principal investigator · Henan Cancer Hospital
K. Zhao
principal investigator · Wuhan Central Hospital
J. Zhao
principal investigator · Peking University Cancer Hospital and Institute
W-R. Yao
principal investigator · Jiangxi Provincial People's Hopital
J-H. Lai
principal investigator · Fujian Medical University Union Hospital
S-Y Maggie. Liu
principal investigator · Guangdong Provincial People's Hospital
Q-T. Yu
principal investigator · Affiliated Cancer Hospital & Institute of Guangzhou Medical University
W-H. Zhao
principal investigator · Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion